The stock of Electromed, Inc. (NYSEMKT:ELMD) is a huge mover today! About 78,137 shares traded hands. Electromed, Inc. (NYSEMKT:ELMD) has declined 7.64% since March 10, 2016 and is downtrending. It has underperformed by 15.16% the S&P500.
The move comes after 9 months positive chart setup for the $36.46M company. It was reported on Oct, 13 by Barchart.com. We have $11.88 PT which if reached, will make NYSEMKT:ELMD worth $58.34M more.
According to Zacks Investment Research, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVestÂ® Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota.”
Insitutional Activity: The institutional sentiment decreased to 1.56 in 2016 Q2. Its down 3.44, from 5 in 2016Q1. The ratio dropped, as 4 funds sold all Electromed, Inc. shares owned while 5 reduced positions. 7 funds bought stakes while 7 increased positions. They now own 649,918 shares or 40.32% less from 1.09 million shares in 2016Q1.
Deutsche Retail Bank Ag last reported 0% of its portfolio in the stock. Creative Planning owns 33,000 shares or 0% of their US portfolio. Lsv Asset last reported 4,700 shares in the company. Vanguard Gp holds 0% of its portfolio in Electromed, Inc. (NYSEMKT:ELMD) for 81,929 shares. Federated Pa, a Pennsylvania-based fund reported 2,943 shares. Goldman Sachs Group has invested 0% of its portfolio in Electromed, Inc. (NYSEMKT:ELMD). Teton Advsr has 0.03% invested in the company for 77,500 shares. Barclays Pcl has 0% invested in the company for 48,600 shares. Acadian Asset Management Limited Liability Co holds 0% of its portfolio in Electromed, Inc. (NYSEMKT:ELMD) for 3,108 shares. Royal Natl Bank Of Canada accumulated 0% or 23,287 shares. Eagle Global Advisors Limited Company reported 34,790 shares or 0% of all its holdings. Blackrock Invest Limited Liability Company has 0% invested in the company for 1,066 shares. Dimensional Fund Advisors Limited Partnership, a Texas-based fund reported 81,724 shares. Wfg Advsrs Limited Partnership holds 0% or 1,000 shares in its portfolio. The Texas-based Bridgeway Mngmt has invested 0.01% in Electromed, Inc. (NYSEMKT:ELMD).
Insider Transactions: Since May 11, 2016, the stock had 2 insider purchases, and 0 insider sales for $552,049 net activity. $299,488 worth of shares were bought by Red Oak Partners – LLC on Wednesday, May 11.
More notable recent Electromed, Inc. (NYSEMKT:ELMD) news were published by: Businesswire.com which released: “Electromed, Inc. to Present at the 5th Annual InvestMNt Conference on August …” on August 17, 2016, also Seekingalpha.com with their article: “A Textbook Muti-Month Wedge Pattern Breakout By Electromed Inc” published on August 29, 2016, Businesswire.com published: “Electromed, Inc. Names John Kowalczyk Vice President of Sales” on February 29, 2016. More interesting news about Electromed, Inc. (NYSEMKT:ELMD) were released by: Businesswire.com and their article: “Electromed, Inc. Reports Higher Fourth Quarter and Full Year Revenues and Profits” published on September 06, 2016 as well as Quotes.Wsj.com‘s news article titled: “Electromed Inc. ELMD (US: NYSE MKT)” with publication date: February 11, 2011.
ELMD Company Profile
Electromed, Inc., incorporated on October 16, 1992, develops, makes and markets airway clearance products, which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company’s products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others. The Firm sells its products to the home healthcare market for patients with chronic lung issues, including bronchiectasis, cystic fibrosis and neuromuscular disease. It also sells its products in acute care settings when the patient is in a post-surgical or intensive care unit, or is admitted for a lung infection brought on by compromised airway clearance. Accordingly, the Company’s sales points of contact include adult pulmonology clinics, cystic fibrosis centers, neuromuscular clinics, pulmonary rehabilitation centers, hospitals and home healthcare centers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.